832
Views
25
CrossRef citations to date
0
Altmetric
Research Paper

Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector

, , , , &
Pages 599-606 | Received 20 Oct 2012, Accepted 06 Nov 2012, Published online: 16 Jan 2013

References

  • Hasleton PS. The internal surface area of the adult human lung. J Anat 1972; 112:391 - 400; PMID: 4564685
  • Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Vaccine 2008; 26:383 - 98; http://dx.doi.org/10.1016/j.vaccine.2007.11.010; PMID: 18082295
  • Zuniga A, Wang Z, Liniger M, Hangartner L, Caballero M, Pavlovic J, et al. Attenuated measles virus as a vaccine vector. Vaccine 2007; 25:2974 - 83; http://dx.doi.org/10.1016/j.vaccine.2007.01.064; PMID: 17303293
  • Liniger M, Zuniga A, Morin TN, Combardiere B, Marty R, Wiegand M, et al. Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. Vaccine 2009; 27:3299 - 305; http://dx.doi.org/10.1016/j.vaccine.2009.01.057; PMID: 19200842
  • del Valle JR, Devaux P, Hodge G, Wegner NJ, McChesney MB, Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol 2007; 81:10597 - 605; http://dx.doi.org/10.1128/JVI.00923-07; PMID: 17634218
  • Brandler S, Lucas-Hourani M, Moris A, Frenkiel MP, Combredet C, Février M, et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 2007; 1:e96; http://dx.doi.org/10.1371/journal.pntd.0000096; PMID: 18160988
  • Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004; 78:146 - 57; http://dx.doi.org/10.1128/JVI.78.1.146-157.2004; PMID: 14671096
  • Liniger M, Zuniga A, Tamin A, Azzouz-Morin TN, Knuchel M, Marty RR, et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine 2008; 26:2164 - 74; PMID: 18346823
  • Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, et al. Viral vectors for malaria vaccine development. Vaccine 2007; 25:2567 - 74; http://dx.doi.org/10.1016/j.vaccine.2006.07.035; PMID: 16914237
  • Dilraj A, Cutts FT, de Castro JF, Wheeler JG, Brown D, Roth C, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 2000; 355:798 - 803; http://dx.doi.org/10.1016/S0140-6736(99)95140-1; PMID: 10711928
  • Dilraj A, Cutts FT, Bennett JV, Fernandez de Castro J, Cohen B, Coovadia HM. Persistence of measles antibody two years after revaccination by aerosol or subcutaneous routes. Pediatr Infect Dis J 2000; 19:1211 - 3; http://dx.doi.org/10.1097/00006454-200012000-00021; PMID: 11144388
  • Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Vaccine 2007; 25:4170 - 4; http://dx.doi.org/10.1016/j.vaccine.2007.03.003; PMID: 17408818
  • Janeway CA, Travers P, Walport M, Schlomchik MJ. Antigen presentation to T Lymphocytes. In: The immune system in health and disease. Garland Science 2008;169-201.
  • Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 2007; 196:Suppl 2 S413 - 20; http://dx.doi.org/10.1086/520603; PMID: 17940978
  • Kiyono H, Fukuyama S. NALT- versus Peyer’s-patch-mediated mucosal immunity. Nat Rev Immunol 2004; 4:699 - 710; http://dx.doi.org/10.1038/nri1439; PMID: 15343369
  • Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6:148 - 58; http://dx.doi.org/10.1038/nri1777; PMID: 16491139
  • STEP study: disappointing, but not a failure. Lancet 2007; 370:1665; http://dx.doi.org/10.1016/S0140-6736(07)61702-4; PMID: 18022020
  • Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science 2008; 321:530 - 2; http://dx.doi.org/10.1126/science.1161000; PMID: 18653883
  • Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J Exp Med 2008; 205:7 - 12; http://dx.doi.org/10.1084/jem.20072681; PMID: 18195078
  • Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:e3548; http://dx.doi.org/10.1371/journal.pone.0003548; PMID: 18958172
  • Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization: a review. Biologicals 1997; 25:323 - 38; http://dx.doi.org/10.1006/biol.1997.0103; PMID: 9325001
  • Wong-Chew RM, Islas-Romero R, García-García MdeL, Beeler JA, Audet S, Santos-Preciado JI, et al. Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis 2004; 189:254 - 7; http://dx.doi.org/10.1086/380565; PMID: 14722890
  • Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al, Vaccine Research Center 004 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650 - 60; http://dx.doi.org/10.1086/509259; PMID: 17109336
  • Marty RR, Knuchel MC, Azzouz-Morin TN, Zuniga A, Ilter O, Wiegand M, et al. An immune competent mouse model for the characterization of recombinant measles vaccines. In preparation
  • Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493 - 7
  • Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613 - 9; http://dx.doi.org/10.1038/nature07352; PMID: 18833271
  • Cutts F. The immunological basis for immunization series, module 7: Measles. World Health Organization 1993; 1-19.
  • Guerbois M, Moris A, Combredet C, Najburg V, Ruffié C, Février M, et al. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology 2009; 388:191 - 203; http://dx.doi.org/10.1016/j.virol.2009.02.047; PMID: 19345390
  • Damjanovic D, Zhang X, Mu J, Medina MF, Xing Z. Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector. Genet Vaccines Ther 2008; 6:5; http://dx.doi.org/10.1186/1479-0556-6-5; PMID: 18261231
  • Bolton DL, Kozlowski P, Rao S, Roederer M, Song K. Fine aerosol adenovirus vaccination against SIV in rhesus macaque. AIDS Res Hum Retroviruses 2008; 24:14
  • Mrkic B, Pavlovic J, Rülicke T, Volpe P, Buchholz CJ, Hourcade D, et al. Measles virus spread and pathogenesis in genetically modified mice. J Virol 1998; 72:7420 - 7; PMID: 9696838

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.